# Telix Pharmaceuticals Ltd: financial statements, quarterly

TLX · Nasdaq · CIK 2007191 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tlx.md) · [Financials](/companies/tlx/financials.md) · [Filings](/companies/tlx/filings.md) · [Insiders](/companies/tlx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tlx/financials.md?period=annual).

## Balance sheet

| Line item | Unit | period not labelled (2022-12-31) | period not labelled (2023-12-31) | period not labelled (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [78.8](/filings/0001628280-26-009943.md) | [84.3](/filings/0001628280-26-009943.md) | [440](/filings/0001628280-26-009943.md) | [142](/filings/0001628280-26-009943.md) |
| Current assets | $m | not reported | [159](/filings/0001628280-26-009943.md) | [570](/filings/0001628280-26-009943.md) | [330](/filings/0001628280-26-009943.md) |
| Total assets | $m | not reported | [277](/filings/0001628280-26-009943.md) | [940](/filings/0001628280-26-009943.md) | [1,164](/filings/0001628280-26-009943.md) |
| Current liabilities | $m | not reported | [111](/filings/0001628280-26-009943.md) | [205](/filings/0001628280-26-009943.md) | [232](/filings/0001628280-26-009943.md) |
| Total liabilities | $m | not reported | [175](/filings/0001628280-26-009943.md) | [587](/filings/0001628280-26-009943.md) | [749](/filings/0001628280-26-009943.md) |
| Shareholders' equity | $m | [54.8](/filings/0001628280-26-009943.md) | [103](/filings/0001628280-26-009943.md) | [353](/filings/0001628280-26-009943.md) | [415](/filings/0001628280-26-009943.md) |

- Cash and equivalents: ifrs-full:CashAndCashEquivalents
- Current assets: ifrs-full:CurrentAssets
- Total assets: ifrs-full:Assets
- Current liabilities: ifrs-full:CurrentLiabilities
- Total liabilities: ifrs-full:Liabilities
- Shareholders' equity: ifrs-full:Equity

Shares outstanding: 338,777,049 at 2025-12-31, from the cover of the [20-F/A filed 2026-03-20](/filings/0001140361-26-010554.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.